Pfizer-BioNTech vaccine 90%-plus effective; Biden-Harris transition's COVID advisory board

• Biden-Harris Transition Announces COVID-19 Advisory Board (Biden-Harris Transition) (CNN) (STAT) (NPR)
• Biden’s ready to start his pandemic response immediately (STAT)
• As Nation Awaits Vaccine, Biden Is Under Pressure to Name New FDA Chief ASAP (KHN)
• ‘They’re not really doing anything’: As Covid-19 cases spiral, leaders around the U.S. lose urgency on prevention (STAT)
• US pharma industry responds to American election result (EPR)
• U.S. crosses 10 million COVID-19 cases as third wave of infections surges (Reuters)
• Experts warn of worsening pandemic unless Trump takes action (The Hill)
• Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly (Pink Sheet)
• What Did US FDA Do Wrong in Its Review Of Aducanumab? AdCom Members Have A List (Pink Sheet)
• Trump tried to justify rising Covid cases by pointing to Europe. Experts say he's wrong. (NBC)
• Six in White House, Including Trump’s Chief of Staff, Have the Coronavirus (NYT)

• COVID-19 vaccine could fundamentally change pandemic direction: WHO (Reuters)
• UK says expects to receive 10 million doses of Pfizer/BioNTech vaccine this year (Reuters)
• UK and EU agree on phased process for Northern Ireland medicines regulation (Pharmatimes)
• NICE launches consultation on its methods of drug evaluation (PMLive)
• Regulatory information – 1.7% and 1.6% increase of pharmacovigilance fees from 1 November 2020 (EMA)
• UK urged to stockpile medicines to confront Covid and Brexi (FT)
• Head of UK’s COVID-19 vaccine taskforce faces questions over biotech fund (Pharmafile)
• Bidencare, a boost for Indian pharmaceutical companies (Economic Times)
• As Covid-19 runs riot across the world, China controls the pandemic (NBC)

• 'Great day for humanity': Pfizer says COVID-19 vaccine over 90% effective (NYT) (Reuters) (STAT) (Endpoints) (NBC) (NPR)
• Health experts want to prioritize people of color for a Covid-19 vaccine. But how should it be done? (STAT)
• Factbox: Development of Pfizer-BioNTech coronavirus vaccine (Reuters)
• Novavax on track to begin U.S. trial of COVID-19 vaccine this month (Reuters)
• Russia's Sputnik V vaccine also over 90% effective: health ministry (Reuters)
• Recommendations for fair and regulated access to a COVID-19 vaccine (AAAS)
• CVS CEO: Pharmacies Ready To Distribute Covid-19 Vaccines Once Approved (Forbes)
• First patient dosed with AgenTus’ cell therapy designed to clear COVID-19 virus while reducing inflammation (BioPharma Reporter)

• Biogen plunges 30% after FDA panel votes against Alzheimer's drug (Reuters)
• GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again (Endpoints)
• Excipient developers call for regulatory facelift (Nature)
• Bristol Myers posts a win for their Otezla competitor in psoriatic arthritis (Endpoints)
• Legend Biotech has a new chairwoman and permanent CEO. But where is Frank Zhang? (Endpoints)
• Opdivo plus Yervoy combo approved in EU for first-line lung cancer (PharmaTimes)
• Patient enrollment bounces back to pre-COVID number: survey
• US green lights AZ’s Brilinta to reduce risk of stroke (PharmaTimes)
• Vifor Builds Its Kidney Disease Focus With $80m Angion Deal (Scrip)
• First patient dosed in COVID-19 trial with allogeneic cell therapy (EPR)
• Sanofi Hampered By Fitusiran Clinical Hold In Hemophilia (Scrip)
• RemeGen grabs one of the world's largest ever biotech IPOs (Fierce Biotech)

• Philips Stellarex Data Furthers Confidence in Paclitaxel Devices (MD+DI)
• Zimmer Biomet shares early data on Apple Watch app for recovery after knee surgery (MedCity News)
• What Intuitive is looking for through its new $100M venture fund (MD+DI)

• The Affordable Care Act Faces Another Supreme Court Test (NYT) (KHN)
• A scalpel, a bulldozer and the Affordable Care Act (SCOTUS Blog)